Skip to main content

Adaptimmune Therapeutics plc (ADAP)

NASDAQ: ADAP · IEX Real-Time Price · USD
0.793
+0.103 (14.91%)
At close: Dec 29, 2023, 4:00 PM
0.790
-0.003 (-0.38%)
After-hours: Dec 29, 2023, 7:55 PM EST

Adaptimmune Therapeutics Revenue

Adaptimmune Therapeutics had revenue of $71.08M in the twelve months ending September 30, 2023, with 305.30% growth year-over-year. Revenue in the quarter ending September 30, 2023 was $7.32M with 4.45% year-over-year growth. In the year 2022, Adaptimmune Therapeutics had annual revenue of $27.15M with 341.50% growth.

Revenue (ttm)
$71.08M
Revenue Growth
+305.30%
P/S Ratio
2.20
Revenue / Employee
$133,105
Employees
534
Market Cap
156.61M USD

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202227.15M21.00M
341.50%
Dec 31, 20216.15M2.19M
55.36%
Dec 31, 20203.96M2.84M
252.76%
Dec 31, 20191.12M-58.38M
-98.11%
Dec 31, 201859.51M21.67M
57.28%
Dec 31, 201737.83M23.64M
166.47%
Dec 31, 201614.20M4.33M
43.84%
Jun 30, 20159.87M9.05M
1,096.48%
Jun 30, 2014825.00K--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

ADAP News

More News